MedTrace Logo

Clinical Outcomes and Ejaculatory Function in BPO Patients Treated With Silodosin

NCT06989515 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2025-06-05

No results posted yet for this study

Summary

This observational study aims to evaluate the relationship between silodosin-induced anejaculation and clinical outcomes in male patients with benign prostatic obstruction (BPO). Silodosin is a commonly used alpha-blocker for lower urinary tract symptoms (LUTS). However, it may cause ejaculatory dysfunction, particularly anejaculation. In this study, patients receiving silodosin for the first time will be grouped based on whether they experience anejaculation or not. Treatment response will be assessed using urinary flow rate, post-void residual urine, and International Prostate Symptom Score (IPSS). Sexual function will be evaluated using the International Index of Erectile Function-5 (IIEF-5) before and after treatment. The study aims to explore whether the presence of anejaculation is associated with improved symptom relief or differences in sexual health.

Conditions

  • Benign Prostate Obstruction (BPO)
  • Lower Urinary Tract Symptom
  • Ejaculatory Dysfunction
  • Anejaculation
  • Silodosin

Sponsors & Collaborators

  • Marmara University

    lead OTHER

Eligibility

Min Age
40 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-15
Primary Completion
2026-03-01
Completion
2026-06-12

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06989515 on ClinicalTrials.gov